

BIOSIGN TECHNOLOGIES INC.

FORM 7 MONTHLY PROGRESS REPORT August 2010

Name of CNSX Issuer	Biosign Technologies Inc. (the "Issuer")
Trading Symbol	BIO
Number of Outstanding Listed Securities	76,368,090
Date	September 6, 2010

Report on Business

1. **General overview/discussion of the development of the Issuer's business and operations over the previous month**

Financing – The Issuer issued 72,500 common shares of Biosign upon exercise of outstanding warrants for total proceeds of \$29,000; In addition, the Issuer issued 35,000 common shares of Biosign upon exercise of employee stock options for total proceeds of \$35,000.

Listing Application – During the period, the issuer received conditional approval to list its common shares on the TSX Venture Exchange. The issuer anticipates listing of its shares in the September.

Sales and Marketing – The Issuer is working closely with key distribution channel partners (master distributors in North America, Europe and Middle East) in preparation for large scale commercial launches of UFIT. Biosign is also continuing discussions with third party payers to establish reimbursement rates for UFIT. The Issuer announced its participation in HealthAchieve, one of the largest and most prestigious health care conferences in North America. The conference will be held in Toronto from November 8-10, 2010.

Production – The Issuer continues to make progress with its key supply chain partners in scaling its hardware manufacturing capabilities for the UFIT platform. The Issuer is also working closely with Dell Inc. to standardize the UFIT platform on Dell IT infrastructure.

2. **General overview and discussion of the activities of management**

During the period, the Issuer experienced losses as anticipated. Revenue is not expected to offset operating expenses in the upcoming quarter as the Issuer continues to focus its efforts on working with strategic distribution channel partners to prepare for large scale deployment of UFIT.

Financing - The Issuer issued 72,500 common shares of Biosign upon exercise of outstanding warrants for total proceeds of \$29,000. All exercises of warrants for the period were at \$0.40 per share. In addition, 35,000 common shares of Biosign were issued under the Issuer's employee stock option plan for total proceeds of \$35,000. All employee option exercises were at \$1.00 per share.

Sales – As in the past, the Issuer continued to develop and expand the Biosign Channel Partner Program "CPP", focusing on Master Distributors for access to global markets. As per the Issuer's European master distribution agreement with Dynamicare AG, it is in the process of working on a

market pilot for the UFIT platform. Under the Middle Eastern master distribution agreement, the Issuer has received initial orders for UFIT. The issuer is in ongoing negotiations with a number of potential resellers and master distributors.

Marketing – The Issuer focuses on addressing key problems in health care. First, on the need for certainty in diagnosis and treatment, which is driven by practical expectations and malpractice concerns. Second, on increasing the accuracy of documentation required for billing, efficiently adding value to clinical care. Third, on enabling real-life monitoring to avoid excessive testing and over-prescribing. It is generally agreed that solutions to these problems are needed to save lives, limbs, money, and time. The Issuer is positioning its UFIT service platform as a comprehensive solution to these problems, starting with the evaluation and management of the most common health risks (blood pressure, blood glucose, and medication).

3. Details of any new products or services developed or offered

All current products are described in the Annual Updated Listing Statement filed with CNSX in April 2010.

4. Details of any products or services that were discontinued

None

5. New business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. Relationships with Related Persons of the Issuer

None

6. Expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced

None

7. Acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month; details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer; details of the relationship

None

8. Describe the acquisition of new customers or loss of customers

See Sales

9. New developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks

None

10. Report on any employee hiring, terminations or lay-offs with details of anticipated length of lay-offs

None

11. Report on applicable labor disputes and resolutions of those disputes

None

12. Details of legal proceedings to which the Issuer became a party and the present status of the proceedings

None

13. Details of indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness

None

14. Details of any securities issued and options or warrants granted.

During the period, the Issuer issued 72,500 common shares of Biosign upon exercise of outstanding warrants for total proceeds of \$29,000. All exercises of warrants for the period were at \$0.40 per share. In addition, 35,000 common shares of Biosign were issued under the Issuer's employee stock option plan for total proceeds of \$35,000. All employee option exercises were at \$1.00 per share.

15. Details of any loans to or by Related Persons

None

16. Details of any changes in directors, officers or committee members

None

17. Trends which are likely to impact the Issuer, including trends in the Issuer's market(s) or political/regulatory trends

Trends are unchanged from the previous period.

FDA releases proposals to update device approval process

The FDA released a set of proposals aimed at clarifying the types of medical devices that can use the 510(k) approval process and when to make medical evidence mandatory for approval. AdvaMed President and CEO Stephen J. Ubl said that although the industry supports the FDA's plan to introduce special requirements for a small group of Class II devices, and that increasing consistency and predictability will help with issues faced by device-makers, the recommendations in total "could result in a significant disruption to a program that has served patients well for more than 30 years." *Wall Street Journal (08/03)*

Device makers' websites should reflect accountable care mandate

Medical-device makers must make sure that their websites are consumer-oriented but compliant with the new "accountable care organization" mandate, John Smith, senior adviser at Dodge Communications, writes in this MassDevice.com blog. Competitive advantage can be achieved if device companies tailor Web content in such a way that it will address customers' key concerns about products and services and create awareness of the ACO policy, Smith writes. *MassDevice.com (Boston) (08/05)*

British Medical Journal Article on the Invalidity of Current Validation Methods

The Lancet medical journal has published a critical perspective on the current methodology of validating health products, arguing that "the statistical gold standard is a fetter on knowledge, wellbeing, and output. It drags down health, raises costs, irritates scientists, and distorts the demand and supply of goods and services by sending incorrect price-quality signals and commodities to the market under the guise of validity and statistical significance. Meantime, good services and commodities are systematically blocked or barely seen through a glass half cracked. There are few scientists who would not rejoice at the breaking of our gold fetters." The author has published a book on the inadequacy of the current approach to validation [1]. Regarding the kind of design currently held as "good clinical trial", the author states: "RCTs fail to yield power, precision, and unbiased errors. Finally, statistical significance—the cornerstone of today's gold standard— is not equal to estimation of magnitudes or minimum important difference. Statistical significance at any level does not prove medical, scientific, or commercial importance." The Issuer trusts that the regulatory agencies will respond to such critiques. Recent developments, such as those mentioned above, suggest to the Issuer that the regulatory climate will soon change for the better, with positive impact on developers of innovative health products and services.

Consumer Self-Care and Telehealth

Today's consumers are willing to explore alternatives such as monitoring and managing chronic disease at home. In 2010 the global market for home blood pressure monitors will reach \$1 billion, home glucose monitoring \$7 billion. Other home testing includes blood coagulation level (PT-INR), a home testing version of this equipment retails for around \$400; cholesterol testing kits are available for \$10 with results available in 15 minutes. Home blood pressure cuffs, diabetes monitors, scales for tracking weight, and even home defibrillators are being marketed today.

¹ Ziliak ST, McCloskey DN. The cult of statistical significance: how the standard error costs us jobs, justice, and lives. Ann Arbor, MI: University of Michigan Press, 2008.

Recognizing that clinicians cannot continue to manage care exclusively with face-to-face visits, thirty-nine percent of doctors are now communicating with their patients online, up from 16% the year previous. Businesses like TelaDoc and ConsultADoctor that offer phone and online visits are thriving – TelaDoc has grown from 300,000 subscribers to over 1 million in a period of 18 months. Recognizing the inefficiency of the individual check-up, counseling for diabetes patients is now offered in group visits.

Meanwhile, physician consistency for seniors is limited, opening the doorway to alternatives. By 2006, only 40% of Medicare patients in the hospital received a visit from a doctor they knew, and only one-third saw their primary doctor when they were in the hospital -- 75% were discharged, unable to name a doctor who treated them. Consequences of this lack of continuity include poorly understood discharge instructions, medication errors, lack of follow-up appointments, and risk of readmission. Consumers are turning to self-treatment and management through home based technologies and online educational content to counter this lack of consistency [2, 3, 4, 5].

2 Calibrated Care is Closer to Home: 2009 Aging and Health Technology, Laurie M. Orlov

3 "Health Care without the Doctor: How New Devices and Technologies Aid Clinicians and Consumers, California HealthCare Foundation,"

Mary Kate Scott, M.B.A. , Scott & Company, Inc. ,2008 <http://www.chcf.org/topics/view.cfm?itemid=133938>

4 Doctors Increasingly Perform Online Visits, <http://www.medicalnewstoday.com/articles/155975.php>

5 Group visit for diabetes patients: <http://clinical.diabetesjournals.org/content/26/2/58.full>

Forward-Looking Statements

This press release contains forward looking statements. Forward looking statements are not based on historical facts, but rather on current expectations, Company assumptions and projections about future events, and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward looking statements. Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding future expectations. Company assumptions and risk factors are listed from time to time in Biosign's reports, public disclosure documents including Management's Discussion and Analysis, Management Information Circular, and in other filings with stock exchanges and securities regulatory authorities in Canada.

You should not place undue importance on forward-looking statements and should not rely upon this information as of any other date. While Biosign may elect to, Biosign is under no obligation and does not undertake to update this information at any particular time. This press release was prepared by management from information available to the date of this Monthly Progress Report.

Certificate of Compliance

The undersigned hereby certifies that:

- 1) The undersigned is a senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
- 2) As of the date hereof there is no material information concerning the Issuer which has not been publicly disclosed.
- 3) The undersigned hereby certifies to CNSX that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all CNSX Requirements (as defined in CNSX Policy 1).
- 4) All of the information in this Form 7 Monthly Progress Report is true.

Dated: September 6, 2010

Signed "Radu Leca"
 Director, President and CEO

Issuer Details Name of Issuer: Biosign Technologies Inc	For Month End August, 2010	Date of Report September 6, 2010
Issuer Address: 175 Commerce Valley Drive West, Suite 230		
City/Province/Postal Code Thornhill, Ontario, L3T 7P6	Issuer Fax No. 905-886-8996	Issuer Telephone No. 416-218-9800
Contact Name Radu Leca	Contact Position CEO	Contact Telephone No. 416-218-9800 ext 234
Contact Email Address ceo@biosign.com	Web Site Address www.biosign.com	

